About Arcturus Therapeutics (NASDAQ:ARCT)
Arcturus Therapeutics Ltd. operates as an RNA medicines company. Its RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 120 patents and patent applications issued in the United States, Europe, Japan, China, and other countries. Its proprietary UNA technology is used to target individual genes in the human genome, as well as viral genes, and other species for therapeutic purposes. The company develops novel RNA therapeutics through its partnerships with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, Synthetic Genomics Inc., and Cystic Fibrosis Foundation Therapeutics Inc. Arcturus Therapeutics Ltd. has a strategic collaboration with CureVac AG to jointly discover, develop, and commercialize novel messenger RNA therapeutics. The company was founded in 2013 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ARCT
CUSIPN/A
Phone972-72-220-4661
Debt
Debt-to-Equity RatioN/A
Current Ratio17.64%
Quick Ratio17.64%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$12.00 per share
Price / Book0.48
Profitability
EPS (Most Recent Fiscal Year)($6.23)
Net Income$-24,600,000.00
Net MarginsN/A
Return on Equity-36.83%
Return on Assets-34.70%
Miscellaneous
Employees19
Outstanding Shares10,690,000
Arcturus Therapeutics (NASDAQ:ARCT) Frequently Asked Questions
What is Arcturus Therapeutics' stock symbol?
Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT."
How were Arcturus Therapeutics' earnings last quarter?
Arcturus Therapeutics (NASDAQ:ARCT) announced its quarterly earnings results on Friday, August, 11th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.15) by $0.02. View Arcturus Therapeutics' Earnings History.
When is Arcturus Therapeutics' next earnings date?
What price target have analysts set for ARCT?
5 analysts have issued 1 year target prices for Arcturus Therapeutics' shares. Their predictions range from $1.00 to $12.00. On average, they anticipate Arcturus Therapeutics' stock price to reach $4.0625 in the next year. View Analyst Ratings for Arcturus Therapeutics.
Who are some of Arcturus Therapeutics' key competitors?
Some companies that are related to Arcturus Therapeutics include Infinity Pharmaceuticals (INFI), ProQR Therapeutics (PRQR), Conatus Pharmaceuticals (CNAT), Trevena (TRVN), CytoDyn (CYDY), Leap Therapeutics (LPTX), Cumberland Pharmaceuticals (CPIX), Oramed Pharmaceuticals (ORMP), Forward Pharma (FWP), RedHill Biopharma (RDHL), Aileron Therapeutics (ALRN), KalVista Pharmaceuticals (KALV), Alpine Immune Sciences (ALPN), Columbia Laboratories (JNP), Flex Pharma (FLKS), Agile Therapeutics (AGRX), Aralez Pharmaceuticals (ARLZ) and Trillium Therapeutics (TRIL).
Who are Arcturus Therapeutics' key executives?
Arcturus Therapeutics' management team includes the folowing people:
- Dr. Stuart J. M. Collinson, Exec. Chairman (Age 58)
- Mr. Mark R. Herbert, Interim Pres
- Mr. Joseph E. Payne M.Sc., Founder
- Ms. Rebecque J. Laba, VP of Fin. & Operations (Age 57)
- Dr. Christine Esau, VP of R&D
Has Arcturus Therapeutics been receiving favorable news coverage?
News coverage about ARCT stock has trended very positive this week, according to Accern. Accern identifies negative and positive news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Arcturus Therapeutics earned a news sentiment score of 0.53 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 45.22 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
How do I buy shares of Arcturus Therapeutics?
Shares of ARCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arcturus Therapeutics' stock price today?
One share of ARCT stock can currently be purchased for approximately $5.70.
How big of a company is Arcturus Therapeutics?
Arcturus Therapeutics has a market capitalization of $57.95 million. The biotechnology company earns $-24,600,000.00 in net income (profit) each year or ($6.23) on an earnings per share basis. Arcturus Therapeutics employs 19 workers across the globe.
How can I contact Arcturus Therapeutics?
Arcturus Therapeutics' mailing address is Azrieli Triangle Building 132 Derech Menachem Begin 39th Floor, Tel Aviv L3, 6701101. The biotechnology company can be reached via phone at 972-72-220-4661 or via email at [email protected]
MarketBeat Community Rating for Arcturus Therapeutics (ARCT)
MarketBeat's community ratings are surveys of what our community members think about Arcturus Therapeutics and other stocks. Vote "Outperform" if you believe ARCT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARCT will underperform the S&P 500 over the long term. You may vote once every thirty days.
Arcturus Therapeutics (NASDAQ:ARCT) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for Arcturus Therapeutics in the last 12 months. Their average twelve-month price target is $4.0625, suggesting that the stock has a possible downside of 28.73%. The high price target for ARCT is $12.00 and the low price target for ARCT is $1.00. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.40 | 2.33 | 2.40 | 2.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
6 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $4.0625 | $3.45 | $1.3125 | $1.6071 |
| Price Target Upside: | 28.73% downside | 38.61% downside | 84.93% downside | 53.06% upside |
Arcturus Therapeutics (NASDAQ:ARCT) Consensus Price Target History
Arcturus Therapeutics (NASDAQ:ARCT) Analyst Ratings History
Show:
(Data available from 4/19/2016 forward)
Arcturus Therapeutics (NASDAQ:ARCT) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 12/28/2012 | monthly | $0.0596 | 6.21% | 1/4/2013 | 1/8/2013 | 1/15/2013 |
| 12/27/2012 | jan 13 | $0.0596 | | | 1/8/2013 | 1/15/2013 |
(Data available from 1/1/2013 forward)
Arcturus Therapeutics (NASDAQ ARCT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.02%
Institutional Ownership Percentage: 9.24%
Arcturus Therapeutics (NASDAQ ARCT) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Arcturus Therapeutics (NASDAQ ARCT) News Headlines
| Source: |
|
Arcturus Therapeutics (NASDAQ:ARCT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Arcturus Therapeutics (NASDAQ:ARCT) Income Statement, Balance Sheet and Cash Flow Statement
Arcturus Therapeutics (NASDAQ ARCT) Stock Chart for Thursday, April, 19, 2018
Loading chart…
